Indian Journal of Urology Users online:1330  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size


 
LETTER TO EDITOR
Year : 2008  |  Volume : 24  |  Issue : 4  |  Page : 581-582
 

Impaired detrusor contractility due to venlafaxine use


1 Department of Neurology, Saint Vincent's Hospital and Medical Centers, New York, NY, USA
2 Comprehensive Epilepsy Center, Department of Neurology, NYP-Weill Cornell Medical Center, New York, NY, USA
3 Department of Neurology, Sir Ganga Ram Hospital, New Delhi, India
4 Department of Medicine, Saint Vincent's Hospital and Medical Centers, New York, NY, USA

Correspondence Address:
N K Sethi
Comprehensive Epilepsy Center, Department of Neurology, NYP-Weill Cornell Medical Center525 East 68th Street, York Avenue, New York, NY 10021
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-1591.44276

Rights and Permissions

 

How to cite this article:
Torgovnick J, Sethi N K, Sethi P K, Arsura E. Impaired detrusor contractility due to venlafaxine use. Indian J Urol 2008;24:581-2

How to cite this URL:
Torgovnick J, Sethi N K, Sethi P K, Arsura E. Impaired detrusor contractility due to venlafaxine use. Indian J Urol [serial online] 2008 [cited 2019 Sep 21];24:581-2. Available from: http://www.indianjurol.com/text.asp?2008/24/4/581/44276


Dear Editor,

Many new serotonergic antidepressants have been introduced into the market over the past decade. As compared to the older tricyclic antidepressants, these usually have a more favorable side-effect profile. As more experience is gained with these newer antidepressants new side-effects are being reported. Venlafaxine (Effexor) has been FDA-approved for the treatment of depression, social anxiety disorder, panic disorder and generalized anxiety disorder. Off-label uses include migraines, diabetic neuropathy and for peri-menopausal symptoms (hot flashes). Common side-effects reported with venlafaxine include nausea, dizziness, sleepiness, sweating, dry mouth, nervousness, insomnia, constipation, confusion, agitation and increased cholesterol. Less common but more serious side-effects such as tachycardia, confusion, changes in vision, mania and seizures have also been documented. [1] We present here a case of a woman who developed impaired detrusor contractility (IDC) due to venlafaxine use, which resolved on drug discontinuation.

A 48-year-old woman presented with complaint of difficulty in voiding urine of 11 days duration. She had a history of multilevel lumbar disk disease and reported lower back and leg pain that preceded the voiding issue. She was menopausal and experienced hot flashes after having recently discontinued hormone replacement therapy. Her only medication was venlafaxine 300 mg daily which she was talking for depression. Apart from tenderness in the lower back, the neurological examination was essentially normal. There was neither clinical evidence for neuropathy nor evidence of lumbosacral root dysfunction to explain her recent onset of difficulty in voiding urine. The magnetic resonance imaging scan was non-revealing. EMG and nerve conduction studies were normal while urodynamic studies were suggestive of IDC with post-void residual more than 200 ml. After considering the possibility of venlafaxine-induced IDC, she was tapered off the medication. Soon after the taper, patient reported return of normal bladder function. Follow-up urodynamic studies were declined by the patient.

Venlafaxine, a combined serotonin-norepinephrine reuptake inhibitor (SNRI), is a relatively new antidepressant drug. There have been reports of male patients experiencing urinary incontinence while taking venlafaxine. [2] Votolato et al., described the case of a 51-year-old woman with bipolar I disorder on venlafaxine who developed urge incontinence requiring the use of four to six pads per day. To reduce her incontinence she found it necessary to void prophylactically every two hours. Her urge incontinence resolved when she was switched from venlafaxine to bupropion, a non-serotonergic antidepressant with noradrenergic and dopaminergic properties. [3] It is worthy to note that duloxetine (Cymbalta) which too is an SNRI is approved in the European Union for the treatment of stress urinary incontinence (SUI). [4] Duloxetine causes an increase in the urethral closure pressure. The authors reviewed all randomized controlled trials comparing duloxetine with placebo or no treatment. The duloxetine group had significantly better quality-of-life scores and rates of symptom improvement for participants on 80 mg daily (weighted mean difference for Incontinence Quality of Life Index for participants on 80 mg daily: 4.5; 95%CI, 2.83-6.18; P<0.00001). They concluded that duloxetine significantly improved the quality of life of patients with SUI, but it was unclear whether or not benefits are sustainable. While the mechanism of action by which venlafaxine causes IDC is unclear, in vivo experiments in animals have shown that both serotonin and norepinephrine have central nervous system effects that affect lower urinary tract function. We wish to add IDC to the list of possible urological side-effects associated with venlafaxine use.

 
   References Top

1.Holliday SM, Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.  Back to cited text no. 1  [PUBMED]  
2.Cavanaugh GL, Martin RE, Stenson MA, Robinson DD. Venlafaxine and urinary incontinence: possible association. Ann Pharmacother 1997;31:372.  Back to cited text no. 2    
3.Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J 2000;11:386-8.  Back to cited text no. 3    
4.Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: A systematic review. Eur Urol. 2007;51:67-74.  Back to cited text no. 4    




 

Top
Print this article  Email this article
Previous article Next article

    

 
   Search
 
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (70 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed8435    
    Printed58    
    Emailed0    
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal

HEALTHWARE INDIA